ARTV – artiva biotherapeutics, inc. (US:NASDAQ)
Stock Stats
News
Artiva Biotherapeutics (NASDAQ:ARTV) was upgraded by analysts at Jefferies Financial Group Inc. to a "strong-buy" rating.
Artiva Biotherapeutics (NASDAQ:ARTV) had its price target raised by analysts at HC Wainwright from $12.00 to $15.00. They now have a "buy" rating on the stock.
Artiva Biotherapeutics GAAP EPS of -$0.88 [Seeking Alpha]
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease [Yahoo! Finance]
Artiva Biotherapeutics Announces Positive Initial Safety and Translational Data Supporting Deep B-Cell Depletion with AlloNK® in Autoimmune Disease
Form 4 Artiva Biotherapeutics, For: Nov 15 Filed by: Horan Christopher
Form 4 Artiva Biotherapeutics, For: Nov 15 Filed by: Raymon Heather
Form 4 Artiva Biotherapeutics, For: Nov 15 Filed by: Bush Jennifer
Form 4 Artiva Biotherapeutics, For: Nov 15 Filed by: Aslan Fred
Form 4 Artiva Biotherapeutics, For: Nov 15 Filed by: Krishnamohan Neha
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.